Bridgebio Pharma, Inc.

BBIO

Pharmaceutical Preparations

Mkt Cap

$4.972B

PE

-9.09

Debt

$434.7M

Cash

$477.5M

EV

$4.929B

FCF

-$604.9M

Market Cap

$4.972B

P/E Ratio

-9.09

Debt

$434.7M

Cash

$477.5M

EV

$4.929B

FCF

-$604.9M

Charts data: {"Earnings":[{"time":"2017-12-30","value":-43832000},{"time":"2018-12-30","value":-169451000},{"time":"2019-12-30","value":-288585000},{"time":"2020-12-30","value":-505488000},{"time":"2021-12-30","value":-586454000},{"time":"2022-12-30","value":-484652000},{"time":"2023-12-30","value":-653251000}],"Sales":[{"time":"2019-12-30","value":40560000},{"time":"2020-12-30","value":8249000},{"time":"2021-12-30","value":69716000},{"time":"2022-12-30","value":77648000},{"time":"2023-12-30","value":9303000}],"Net Margins":[{"time":"2019-12-30","value":-7.115014792899408},{"time":"2020-12-30","value":-61.27870044853922},{"time":"2021-12-30","value":-8.412043146480004},{"time":"2022-12-30","value":-6.241654646610344},{"time":"2023-12-30","value":-70.21939159410942}],"Assets":[{"time":"2018-12-30","value":464941000},{"time":"2019-12-30","value":631679000},{"time":"2020-12-30","value":703588000},{"time":"2021-12-30","value":1012792000},{"time":"2022-12-30","value":623036000},{"time":"2023-12-30","value":546380000}],"Stockholders Equity":[{"time":"2017-12-30","value":88349000},{"time":"2018-12-30","value":377240000},{"time":"2019-12-30","value":473733000},{"time":"2020-12-30","value":106256000},{"time":"2021-12-30","value":-867002000},{"time":"2022-12-30","value":-1243335000},{"time":"2023-12-30","value":-1343013000}],"ROE":[{"time":"2017-12-30","value":-0.49612332906993856},{"time":"2018-12-30","value":-0.449186194465062},{"time":"2019-12-30","value":-0.6091722552577085},{"time":"2020-12-30","value":-4.75726547206746},{"time":"2021-12-30","value":0.6764159713587743},{"time":"2022-12-30","value":0.3898000136729039},{"time":"2023-12-30","value":0.48640705637249976}],"ROA":[{"time":"2018-12-30","value":0.3699351100462209},{"time":"2019-12-30","value":0.4707295952532853},{"time":"2020-12-30","value":0.7705404299106864},{"time":"2021-12-30","value":-0.5693488890117615},{"time":"2022-12-30","value":-0.8221065877413183},{"time":"2023-12-30","value":-1.1116256085508254}]}

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Sector

10-Q
9/30/23
10-Q
6/30/23
10-Q
3/31/23
10-K
12/31/22
10-Q
9/30/22
10-Q
6/30/22
10-Q
3/31/22
10-K
12/31/21
10-Q
9/30/21
10-Q
6/30/21
10-Q
3/31/21
10-K
12/31/20
10-Q
9/30/20
10-Q
6/30/20
10-Q
3/31/20
10-K
12/31/19
10-Q
9/30/19
10-Q
6/30/19

Chart P/E ratio

In the chart Earnings are multiplied by this value.

Earnings Growth -

Earnings Stability -

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

The Net Margin is too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Over time the ROA has been decreasing indicating a lower marginal ROA with respect to the calculated one, this could impede growth.

Years	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Net Margin	-	-	-710%	-6.1K%	-840%	-620%	-7K%	-250%
ROA	-	37%	47%	77%	-57%	-82%	-110%	-57%
ROE	-50%	-45%	-61%	-480%	68%	39%	49%	53%

What is the average Net Margin?

The average Net Margin over the past 5 years is -3.07K%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -711.72%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -14.86%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is -36.07%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -71.05%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +37.45%.

Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Under the assumption that FCF does not diminish and debt does not increase, the current years to repay the debt are acceptable.

Data are missing

Years	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Debt FCF	-	-	-0.37	-0.23	-0.84	-1.02	-0.84	-0.72
Debt Equity	-	0.14	0.20	0.90	-0.50	-0.35	-0.33	-0.42
MIN
Graham Stability	-	-	-	-	-	-	-	-

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -0.72.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -0.17.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Data are missing

Years	12-2018	12-2020	12-2022	Trend
Revenue	-	4.1%	-88%	-76%
Net Income	-	-	-	-
Stockholders Equity	-	-	-	-200%
FCF	-	-	-	-

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is -.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -75.88%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is +30.98%.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -202.28%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is +30.68%.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.